Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 1Q

Singulair sales were $1.2 billion (+10%). Remicade sales were $674 million (+30%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

1Q Revenues:$11.4 billion (revenues were $5.4 billion in 1Q09)
1Q Earnings: $330.2 million (-77%)
Comments: Revenuegrowth in the quarteris largely due to the inclusion of legacy Schering-Plough operations. Singulair sales were $1.2 billion (+10%). Remicade sales were $674 million (+30%). Nasonex sales were $320 million (+4%). Fosamax sales were $230 million (-12%). Clarinex sales were flat at $174 million. Zetia sales were up 5% to $534 million. Vytorin sales were flat at $477 million. Januvia and Janumet sales were $511 million (+24%) and $201 million (+56%), respectively. Isentress sales were up 57% to $232 million. Cozaar / Hyzaar sales were $782 million (-7%). Varivax sales were $319 million (+27%). Gardasil sales were down 11% to $233 million. R&D expenses were up 66% to $2.0 billion. Results include $2.3 billion of expenses related to the Merck/Schering-Plough merger. Restructuring costs were $287.7 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters